Glow Peptides · Research Journal

Tesamorelin Lot Documentation: Verifying Identity and Purity

Glow Peptides Research Team · 2026-09-17

For research use only. Not for human or veterinary use, diagnostic use, or in any therapeutic application.

Tesamorelin is a long synthetic peptide, and long synthetic peptides are where analytical documentation stops being a formality. A 44-residue chain is assembled one residue at a time, and every step is an opportunity for the finished material to be slightly other than what the label says. This guide covers what the documentation for a tesamorelin lot contains — how identity is established, why a purity figure on a long sequence is a harder target than on a short one, and how to check that the vial in your hand is the vial the paperwork describes. The lot on file is 260203QLTE10, and its material page is tesamorelin.

If you have not read a certificate of analysis before, the field-by-field walkthrough in the shorter guide on how to read a peptide certificate of analysis covers the layout of the document itself. This page assumes that layout and goes a level deeper: what the two instruments can and cannot settle for a chain this long, and where the limits of a single-lot record sit.

The lot is the unit, not the compound

Be clear first about what is being documented. A certificate does not describe tesamorelin. It describes one batch of material that was synthesised, purified, sampled and analysed as a unit, on the date it was measured. The next batch is a separate chemical event with its own yield, its own impurity profile and its own record.

This distinction is not pedantry. Solid-phase peptide synthesis is a repetitive process, and repetitive processes drift. Coupling efficiency varies with resin loading, reagent quality, temperature and scale, and purification recovers a different fraction each run. Two batches of the same sequence, made by the same facility on the same equipment, will not have identical chromatograms. That is ordinary chemistry rather than a fault, and it is why the analysis is repeated per batch instead of performed once and reused.

The practical consequence: the question to ask is never "do you test tesamorelin". Every supplier answers yes. The question is whether the specific lot number printed on the vial resolves to its own record.

Reading the identifiers: catalog code and lot number

Two strings carry the identity of a Glow vial. The catalog code names the material and its content; the lot number names the batch.

The catalog code is a two-letter compound abbreviation followed by the total peptide content in milligrams. TE10 is tesamorelin at 10 mg. BC10 is BPC-157 at 10 mg. EP50 is epithalon at 50 mg. A trailing -C marks a capsule format rather than a lyophilized vial. The code is a content descriptor and nothing more: the milligram figure states how much peptide is sealed in the container, and it is not a quantity for any other purpose.

The lot number wraps that code in batch context: a six-digit date in YYMMDD form, a short supplier code identifying the manufacturing source, then the catalog code. In 260203QLTE10, the segments read as 26-02-03, supplier QL, material TE10. Supplier codes seen across the catalog include QL, HP, ZJ and SXH. Punctuation varies between batches — some lots carry hyphens, some run the segments together — so match on the content of the string rather than its formatting.

Reading the string this way gives you something to falsify. A lot number that does not decompose sensibly — a material code disagreeing with the product name, a date outside any plausible batch window — is worth a second look before you rely on the document.

Identity: what mass spectrometry settles for a long chain

Identity is logically prior to purity. A purity figure answers "how much of this sample is the main component". It says nothing about whether that component is the right molecule. A very clean sample of the wrong sequence produces an excellent chromatogram. Only a mass measurement closes that gap.

Mass spectrometry works by ionising the sample and measuring mass-to-charge ratio. The observed mass is compared against the mass calculated from the intended sequence — the sum of the residue masses along the chain, adjusted for the terminal chemistry and any modification the sequence specifies. If observed and calculated agree within the method's tolerance, the material is consistent with the intended sequence.

Why the test matters more as the chain gets longer

For a short peptide, a great deal can be inferred from retention behaviour alone, because there are only so many ways a handful of residues can be assembled. A 44-residue chain is different in kind. The number of possible near-miss structures grows with the number of coupling steps, and many of those near-misses differ from the target by a single residue. A mass measurement is the practical way to distinguish them, because a missing or substituted residue changes the molecular mass by a defined amount.

Resolution matters here too. A longer peptide carries multiple charges under electrospray conditions and appears as a series of charge states rather than a single line, and the gap between the target and a single-residue deletion is a small fraction of a large total mass. A method adequate for a short peptide is not automatically adequate for a long one, which is one reason the method belongs next to the result.

What a mass match does not establish

A mass match is a strong statement and a narrow one. Three limits are worth holding in mind.

• Mass is not sequence. Two arrangements of the same residues share a mass. Routine confirmation establishes composition consistent with the intended sequence; it does not read the sequence off the molecule. Sequencing is a separate experiment.
• Isobaric substitutions are invisible. Certain residue swaps produce no mass change at all, and others produce a change too small to resolve at a mass this large without high-resolution instrumentation.
• Identity is not quantity. Confirming the target is present says nothing about how much of the sample it represents. That is the other instrument's job.

The longer account of both instruments, including why a purity percentage is only meaningful alongside the method that produced it, is in the guide on HPLC and mass spectrometry.

Purity: why 44 residues is a harder target

Reverse-phase HPLC separates a sample's components by how strongly each partitions onto a hydrophobic stationary phase as a solvent gradient carries it through the column. Components emerge at different times, a detector records each as a peak, and purity is reported as the target peak's area against total detected peak area.

That sounds equally straightforward for any peptide. It is not, and the reason is arithmetic. Each coupling step in solid-phase synthesis proceeds at some efficiency slightly below perfect, and those shortfalls compound. A step efficiency that yields a very clean product over eight cycles yields a visibly messier one over forty-four, because the proportion of chains that completed every step falls multiplicatively. Longer sequences start from a worse crude mixture and lean harder on purification to reach the same specification.

The species purification has to remove are not random. They fall into recognisable families, and knowing the families is what turns a chromatogram into information.

The hardest impurities to remove are the ones most similar to the target, which makes a purity figure on a long peptide more sensitive to the chromatographic method than the same figure on a short one. Change the column chemistry, the gradient slope or the run time and a shoulder that was resolved becomes a shoulder that was integrated into the main peak.

Glow's published specification is a floor of ≥99.2% by reverse-phase HPLC under the method stated on each certificate. A floor is a different kind of statement from a typical or average value: it is the minimum every released lot has to clear, not a figure some lots reach. The synthesis side of this — why the route taken determines which impurity families you are fighting — is covered in the companion article on solid-phase versus liquid-phase peptide synthesis and purity.

What the certificate contains, and what it is silent about

Glow's per-lot certificates are issued by an independent laboratory, Freedom Diagnostics, named on the documents themselves. Purity is determined by reverse-phase HPLC and identity by mass spectrometry. Every released lot's record is public at the quality and COA directory and at its own /coa/ address, with no account or request in the way. The QR code on a vial opens the record for that vial's lot rather than a product-level page.

The right-hand column is the honest half of the document. A purity figure of ≥99.2% under a stated HPLC method means no more than 0.8% of detected material was anything other than the target. Species the detector does not respond to are not in the calculation — a real limit of the technique rather than a criticism of it, and the reason identity confirmation by mass is not optional. Where a lot's report includes additional attributes, those results apply to that lot, never to the catalog as a whole.

Matching the vial to the paperwork

Verification is a short sequence, and it needs the vial as well as the document. A certificate read on its own is a claim about material you may or may not be holding.

1. Read the lot number off the label, not off the listing. The string on the container is the authoritative one. Note its exact characters, including any suffix.
2. Open that lot's record. Scan the QR code or search the lot number in the COA directory. The record that opens should carry the same lot number, not a similar one.
3. Check the catalog code against the vial. TE10 on the record and a 10 mg tesamorelin label agree. A mismatch in the material code is a mismatch in the material.
4. Confirm both methods are named. Identity with no method behind it is an assertion; purity with no method behind it is a number that cannot be compared to anything.
5. Check that the laboratory is named. "An accredited independent laboratory" is a description. A name is something you can look up.
6. Check the report date against the batch date in the lot number. A report predating the batch, or postdating it by an implausible margin, describes other material.

To work compound by compound rather than vial by vial, the COA lookup by compound index is the faster entry point. The mechanics of the document itself — every field, in order — are in certificates of analysis explained.

Three lots, read side by side

The same documentation structure applies across very different materials. Each link below opens that lot's own record.

Note what changes between the rows and what does not. The compound abbreviation and the content figure change; the structure of the identifier does not. The supplier code differs between the QL and HP batches, which says where a batch came from rather than anything about its quality. Epithalon is a short sequence and tesamorelin a long one, which changes how difficult the same purity floor is to hit but not what the document must state. The analytical burden differs; the documentation standard does not.

What one certificate cannot tell you about the next one

This is the limit most often overstated in this industry, so it is worth stating plainly alongside the strengths.

A certificate for lot 260203QLTE10 is evidence about lot 260203QLTE10. It is not evidence about the lot before it, the lot after it, or a different compound from the same supplier. Any inference from one lot to a supplier's practice in general is an inference about process consistency, and a single document cannot support it.

What can support it is a run of records. If every released lot has a published certificate, from the same named laboratory, by consistent methods, reachable without asking, the pattern across those documents is itself the evidence — not because any one of them proves more than it says, but because a supplier who publishes everything has removed the option of publishing selectively. A supplier with one immaculate certificate on the landing page and nothing behind it has shown you their best batch, which is the batch least informative about the others.

Storage conditions for a lyophilized reference lot

A certificate describes material as analysed, on the date of analysis. Everything after that point is a matter of conditions. Lyophilized peptide is a dry solid, and its stability rests on staying dry; three conditions carry most of the load.

• Temperature. Degradation pathways are temperature-dependent. Cold storage slows them; ambient storage does not. The condition stated for the material is the one that applies.
• Light. Some side chains are photosensitive, and oxidation is among the impurity families a chromatogram will eventually show. Shielded storage removes that variable.
• A sealed container. Lyophilized material is hygroscopic, and moisture ingress reintroduces the conditions under which hydrolysis and deamidation proceed. A seal broken to air is the most consequential change to a dry solid's environment.

These are conditions, not procedures. The point for documentation is narrower still: a certificate is a measurement record, not a warranty extending forward in time. Two vials from the same lot, stored differently, are described by the same document and are no longer in the same state. That is not a weakness in the document. It is the boundary of what any analytical record can claim.

Red flags on a tesamorelin certificate

When you are evaluating documentation from a supplier you do not already trust, these are the failures that matter most, roughly in order of seriousness.

• No lot number anywhere on the document. Without it, the certificate cannot be connected to any particular material, and nothing else printed on it applies to your vial.
• A lot number that is not the one on your label. A close-but-different string is a different batch. A supplier who sends "the certificate for that product" instead has answered a question you did not ask.
• Identity asserted with no method. A line reading "Identity: conforms" with no instrument named is a statement of belief. For a 44-residue sequence in particular, identity without a mass measurement behind it is the weakest point a document can have.
• A purity figure with no chromatographic method stated. Column, gradient and detection determine the number. Without them it cannot be compared, reproduced or challenged.
• The laboratory described rather than named. Independence that cannot be checked has not been established.
• Documentation supplied only on request. A record you can open without asking existed before you asked.
• One document covering an entire catalog. Certificates describe batches. A product-level document is a category error, whatever is printed on it.
• Round numbers. Real chromatographic integration produces uneven figures, rarely round ones. Identical round values across a page suggest numbers written rather than measured.
• A purity claim stated as a typical or average value. An average tolerates lots below it, by definition. A floor does not.

Frequently asked questions

How do I check that a tesamorelin vial matches its certificate?

Start from the label, not the listing. Read the lot number printed on the vial, then open that lot's record — the QR code goes straight to it, or search the number in the public COA directory. The record should carry the identical lot number and a catalog code that agrees with the vial: TE10 for tesamorelin at 10 mg total peptide content. A number merely similar to the one on your label is a different batch and does not describe your material.

What does mass spectrometry establish about a tesamorelin lot?

It establishes that the observed molecular mass agrees with the mass calculated from the intended sequence, within the method's tolerance. For a 44-residue chain that is the practical way to rule out the most common synthesis by-products, because a missing or substituted residue shifts the mass by a defined amount. What it does not do is read the sequence off the molecule: rearrangements of the same residues share a mass, and certain substitutions are isobaric. Identity confirmation is a statement about composition, not a sequencing experiment.

Why is purity harder to achieve on a longer peptide sequence?

Because shortfalls compound. Each coupling step in solid-phase synthesis runs slightly below perfect efficiency, and the fraction of chains that completed every step falls multiplicatively with the number of steps. A sequence of forty-four residues therefore starts from a messier crude mixture than a short one and leans harder on purification. The impurities that survive are the hardest to separate, because a chain missing one internal residue behaves on the column almost exactly like the target.

What does 10 mg mean on a tesamorelin vial?

It is the total peptide content sealed in that vial — a content specification for the container. It describes what is inside, and it is not a quantity for any other purpose. The figure also appears inside the catalog code: TE10 means tesamorelin at 10 mg, in the same way EP50 means epithalon at 50 mg and BC10 means BPC-157 at 10 mg. A trailing "-C" marks a capsule format rather than a lyophilized vial.

Does one tesamorelin certificate cover every lot a supplier sells?

No, and a supplier presenting it that way has misunderstood the document. Peptide manufacturing is a batch process: each batch has its own yield, its own impurity profile and its own analysis. A certificate is evidence about the batch that was sampled, on the date it was measured, and nothing else. What a single record cannot establish, a complete set can — if every released lot has a published record, the pattern across them is the evidence of consistency.

More research articles · Browse research peptides